House Bill 3446
116th Congress(2019-2020)
National Commission on Scleroderma and Fibrotic Diseases Act of 2019
Introduced
Introduced in House on Jun 24, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3446
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Peter King
grade
New York
California
California
California
Colorado
Colorado
Colorado
Colorado
Florida
Illinois
Iowa
Maine
Maryland
Massachusetts
Michigan
Michigan
Minnesota
Mississippi
Missouri
Nevada
New Jersey
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
Ohio
Pennsylvania
Puerto Rico
Texas
Vermont
Virginia
Washington
Washington
Washington
Washington
Washington
Washington
Wisconsin
No House votes have been held for this bill.
Summary
National Commission on Scleroderma and Fibrotic Diseases Act of 2019
This bill temporarily establishes a National Commission on Fibrotic Diseases within the National Institutes of Health that must recommend improvements regarding fibrosis and fibrotic disease research.
June 24, 2019
06/25/2019
Referred to the Subcommittee on Health.
06/24/2019
Referred to the House Committee on Energy and Commerce.
06/24/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:50:56 PM